GENPREX (GNPX) Competitors $0.17 +0.00 (+1.16%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.17 0.00 (-0.40%) As of 08/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. FNCH, ELEV, CING, LSTA, RLMD, AYTU, DARE, LSB, CMMB, and PMNShould you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include Finch Therapeutics Group (FNCH), Elevation Oncology (ELEV), Cingulate (CING), Lisata Therapeutics (LSTA), Relmada Therapeutics (RLMD), Aytu BioPharma (AYTU), Dare Bioscience (DARE), LakeShore Biopharma (LSB), Chemomab Therapeutics (CMMB), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. GENPREX vs. Its Competitors Finch Therapeutics Group Elevation Oncology Cingulate Lisata Therapeutics Relmada Therapeutics Aytu BioPharma Dare Bioscience LakeShore Biopharma Chemomab Therapeutics Promis Neurosciences GENPREX (NASDAQ:GNPX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Do institutionals & insiders hold more shares of GNPX or FNCH? 14.1% of GENPREX shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 0.4% of GENPREX shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, GNPX or FNCH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENPREXN/AN/A-$21.11MN/AN/AFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.47 Does the media prefer GNPX or FNCH? In the previous week, GENPREX and GENPREX both had 1 articles in the media. GENPREX's average media sentiment score of 1.88 beat Finch Therapeutics Group's score of 0.00 indicating that GENPREX is being referred to more favorably in the media. Company Overall Sentiment GENPREX Very Positive Finch Therapeutics Group Neutral Which has more volatility & risk, GNPX or FNCH? GENPREX has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Is GNPX or FNCH more profitable? Finch Therapeutics Group's return on equity of -69.14% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets GENPREXN/A -809.27% -386.95% Finch Therapeutics Group N/A -69.14%-26.92% SummaryFinch Therapeutics Group beats GENPREX on 5 of the 7 factors compared between the two stocks. Get GENPREX News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.78M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.0831.2626.59Price / SalesN/A361.89431.16158.34Price / CashN/A44.6737.7359.36Price / Book4.378.0910.046.68Net Income-$21.11M-$54.08M$3.27B$265.59M7 Day Performance3.80%-0.41%1.34%0.66%1 Month Performance-30.76%6.23%6.13%2.64%1 Year Performance-73.98%10.45%41.90%22.36% GENPREX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGENPREX1.8653 of 5 stars$0.17+1.2%N/A-74.9%$5.78MN/A0.0020Positive NewsFNCHFinch Therapeutics Group0.3175 of 5 stars$13.48+12.1%N/A+1.6%$21.65MN/A-1.53190High Trading VolumeELEVElevation Oncology1.3166 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540CINGCingulate2.3899 of 5 stars$3.99+2.3%$26.00+551.6%-50.8%$21.11MN/A-0.9720Analyst RevisionGap UpLSTALisata Therapeutics2.5074 of 5 stars$2.47+2.9%$23.50+851.4%-14.5%$21.01M$1M-1.1130Analyst RevisionGap DownRLMDRelmada Therapeutics4.6366 of 5 stars$0.61-0.4%$5.00+719.7%-70.1%$20.33MN/A-0.2710Positive NewsAYTUAytu BioPharma3.7648 of 5 stars$2.18+1.4%$10.00+358.7%-4.1%$19.30M$81M-3.03160Positive NewsDAREDare Bioscience2.5111 of 5 stars$2.10+1.9%$12.00+471.4%-40.3%$18.60M-$17.70K-0.9830LSBLakeShore Biopharma1.1758 of 5 stars$0.84flatN/A-81.9%$17.36M$85.67M0.00773News CoverageCMMBChemomab Therapeutics3.2487 of 5 stars$0.89-3.6%$8.50+860.5%-54.2%$17.31MN/A-1.5020News CoverageAnalyst ForecastGap UpPMNPromis Neurosciences3.2339 of 5 stars$0.55+4.6%$4.33+689.3%-60.8%$17.16MN/A-2.615Positive News Related Companies and Tools Related Companies FNCH Competitors ELEV Competitors CING Competitors LSTA Competitors RLMD Competitors AYTU Competitors DARE Competitors LSB Competitors CMMB Competitors PMN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENPREX Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access